PSMA antibody, humanized PSMA.CAR10.3, or Cetuximab increases prostate cancer localization of NF-κB p50-deficient immature myeloid cells (p50-IMC) and phagocytosis by their macrophage progeny

PSMA antibody, humanized PSMA.CAR10.3, or Cetuximab increases prostate cancer localization of NF-κB p50-deficient immature myeloid cells (p50-IMC) and phagocytosis by their macrophage progeny

Abstract Adoptive transfer of immature myeloid cells lacking the repressive NF-κB p50 subunit (p50-IMC) slows the growth of syngeneic murine prostate cancer and other tumors. Directing p50-IMC to tumors using Fc receptor-bound antibodies (Abs) or surface chimeric antigen receptors (CARs) may increas...

Full description

Saved in:
Bibliographic Details
Main Authors: Mohammad A. Alzubi, Theresa Barberi, Alan D. Friedman
Format: Article
Language:English
Published: Springer 2025-02-01
Series:Cancer Immunology, Immunotherapy
Subjects:
Myeloid
Immunotherapy
NF-κB p50
Prostate cancer
PSMA
EGFR
Online Access:https://doi.org/10.1007/s00262-024-03939-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items